Conversion from standard cyclosporine to neoral in lung transplant recipients

Transplantation Proceedings

Volumn 30, Issue 5, 1998, Pages 1895-1897

  Kesten, S ^a   Scavuzzo, M ^b   Laurin, L ^c   Tan, A ^c   Chaparro, C ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c Novartis Pharmaceuticals   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

ADULT; AREA UNDER THE CURVE; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; GRAFT SURVIVAL; HUMAN; LUNG TRANSPLANTATION; MALE; MICROEMULSION; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; CREATININE; CYCLOSPORINE; FEMALE; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LUNG TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED;

EID: 0031661720     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(98)00473-4     Document Type: Conference Paper

References (7)

1. Kovarik JM, Mueller EA, Richard F, et al: Transplantation 62:759, 1996
2. Freeman D, Grant D, Levy G, et al: Ther Drug Monit 17:213, 1995
3. Drewe J, Meirer R, Vonderscher J, et al: Br J Clin Pharmacol 34:60, 1992
4. Wong PY, Ma J: Transplant Proc 22:1166, 1990
5. Lemaire M, Fahr A, Maurer G: Transplant Proc 22:1110, 1990
6. Ohlman S, Lindholm A, Hagglund H, et al: J Clin Pharmacol 44:265, 1993
7. Kesten S, Scavuzzo M, Chaparro C, et al: Am J Resp Crit Care Med 153:A265, 1996